Filing Flows › bioAffinity Technologies (BIAF) › Q3 2026
bioAffinity Technologies (BIAF) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 6, 2026
bioAffinity Technologies (BIAF) reported revenue of $1.1M for the third quarter 2026 (Q3 2026), -26% from a year earlier and -29% from the quarter before. Operating margin was -328.0%, net loss $5.3M (493.1% of revenue).
bioAffinity Technologies, Q3 2026: revenue $1.1M (-26% year over year), operating margin -328.0%, net loss $5.3M, operating cash flow −$3.9M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.1M | -29% | -26% |
| Operating profit | −$3.5M | — | — |
| Net earnings | −$5.3M | — | — |
| Operating cash flow | −$3.9M | — | — |
What changed
Revenue was $1.1M in Q3 2026, down 26% year over year and down 29% from the previous quarter. Health Care, Patient Service was the largest line at 81% of revenue. Health Care, Patient Service lost $309K year over year (down 26%), 82% of the total change.
Operating costs exceeded revenue by $3.5M, an operating margin of -328.0%. Total costs grew 23% against a revenue fall of 26%. The fastest-growing cost line was SG&A (+25%). The quarter ended with a net loss of $5.3M, wider than the previous quarter's $3.4M loss.
Operating cash flow was −$3.9M. Non-cash charges added back $67K of depreciation and amortization and $139K of share-based compensation. Working capital and other items added $1.2M. Capital expenditures of $77K exceeded it, leaving free cash flow of −$3.9M.
Questions
What was bioAffinity Technologies' revenue in the third quarter 2026?
bioAffinity Technologies (BIAF) reported revenue of $1.1M for the third quarter 2026 (Q3 2026), -26% from a year earlier and -29% from the quarter before.
Was bioAffinity Technologies profitable in the third quarter 2026?
Operating loss was $3.5M (-328.0% of revenue) and net loss $5.3M.